10-Q quarterly report · filed Nov 9, 2026

Aura Biosciences, Inc. (AURA) Q3 2026 10-Q Quarterly Report

Short answer

Aura Biosciences, Inc. (AURA) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$32M
−22.7% YoY · +29.7% QoQ
EPS (diluted)
−$0.24
+36.8% YoY · +50.0% QoQ

Source: XBRL data from the Aura Biosciences, Inc. (AURA) Q3 2026 10-Q on SEC EDGAR. USD.

Aura Biosciences, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no products approved for sale
  • Net loss $32.1M vs $26.1M YoY, operating expenses $35.1M vs $27.9M
  • R&D $24.7M vs $22.2M, clinical trials $9.3M vs $6.9M, strongest spending area
  • Cash, equivalents and marketable securities $297.2M, funding operations into first half of 2029
  • Operating cash use $88.8M vs $64.3M, financing provided $242.3M after $280.8M offering proceeds and $39.0M repurchase

Risk Factors

  • Pivotal Phase 3 enrollment completed, but topline data not expected until second half of 2027, delaying potential approval and commercialization
  • EMA-required drug-substance characterization testing delayed Phase 3 enrollment authorization under EU Clinical Trial Regulation
  • Single-source manufacturing for bel-sar regulatory materials, drug substance, and drug product heightens supply interruption risk
  • Cash and marketable securities fund operations into first half of 2029, but additional capital needed to complete bel-sar development
  • 2026 Sales Agreement permits up to $200.0 million in common-stock offerings, creating potential shareholder dilution

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Aura Biosciences, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.